Purple Biotech (PPBT) Free Cash Flow (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Free Cash Flow of -$3.1 million for Q1 2026, down 57.79% year-over-year from -$7.4 million in Q1 2025, and down 192.5% quarter-over-quarter from -$1.1 million in Q4 2025.
Purple Biotech (PPBT) Free Cash Flow (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Free Cash Flow for 10 consecutive years, with -$3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 57.79% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at -$6.8 million (up 39.63% YoY), while the FY2025 annual figure was -$5.7 million, up 60.61% from the prior year.
- Free Cash Flow fell to -$3.1 million in Q1 2026 per PPBT's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.1 million in Q3 2025 and bottomed at -$6.1 million in Q1 2023.
- Historically, Free Cash Flow has averaged -$3.5 million across 5 years, with a median of -$3.7 million in 2023.
- Annual changes were most pronounced in 2025 — Free Cash Flow soared 67.62% — and 2026, when it tumbled 57.79%.
- Purple Biotech's Free Cash Flow stood at -$4.3 million in 2022, then retreated by 16.92% to -$5.0 million in 2023, then soared by 59.62% to -$2.0 million in 2024, then jumped by 47.02% to -$1.1 million in 2025, then sank by 192.5% to -$3.1 million in 2026.
- Business Quant data shows PPBT's Free Cash Flow at -$3.1 million in Q1 2026, -$1.1 million in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | -2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.12 Mn |
| Mar 31, 2026 | -3.12 Mn |
| Dec 31, 2025 | -1.07 Mn |
| Dec 31, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.54 Mn |
| Jun 30, 2025 | -1.54 Mn |
| Mar 31, 2025 | -1.98 Mn |
| Mar 31, 2025 | -1.98 Mn |
| Dec 31, 2024 | -2.01 Mn |
| Dec 31, 2024 | -2.01 Mn |
| Sep 30, 2024 | -3.30 Mn |
| Sep 30, 2024 | -3.30 Mn |
| Jun 30, 2024 | -3.98 Mn |
| Jun 30, 2024 | -3.98 Mn |
| Mar 31, 2024 | -5.08 Mn |
| Mar 31, 2024 | -5.08 Mn |
| Dec 31, 2023 | -4.99 Mn |
| Dec 31, 2023 | -4.99 Mn |